Chemomab Therapeutics (CMMB) Insider Trading & Ownership $1.22 +0.02 (+1.44%) As of 06/12/2025 03:59 PM Eastern Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Chemomab Therapeutics (NASDAQ:CMMB) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage11.91%Number OfInsiders Buying(Last 3 Years)0Number OfInsiders Selling(Last 3 Years)3Amount OfInsider Selling(Last 3 Years)$1.89M Get CMMB Insider Trade Alerts Want to know when executives and insiders are buying or selling Chemomab Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CMMB Insider Buying and Selling by Quarter Chemomab Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails1/3/2023Israel Gp Ltd. OrbimedMajor ShareholderSell336,900$3.58$1,206,102.00 11/16/2022George Adi MorInsiderSell324,775$2.08$675,532.00 11/16/2022Neil Harris CohenDirectorSell2,409$2.00$4,818.00 (Data available from 1/1/2013 forward) CMMB Insider Trading Activity - Frequently Asked Questions Who is on Chemomab Therapeutics's Insider Roster? The list of insiders at Chemomab Therapeutics includes George Adi Mor, Israel Gp Ltd. Orbimed, and Neil Harris Cohen. Learn more on insiders at CMMB. What percentage of Chemomab Therapeutics stock is owned by insiders? 11.91% of Chemomab Therapeutics stock is owned by insiders. Learn more on CMMB's insider holdings. Chemomab Therapeutics Key ExecutivesDr. Adi Mor George Ph.D. (Age 42)Co-Founder, Chief Scientific Officer, CEO & Executive Director Compensation: $330kMs. Sigal Fattal CPA (Age 53)M.B.A., Chief Financial Officer Compensation: $322kDr. Matthew B. Frankel M.B.A. (Age 55)M.D., Chief Medical Officer & VP of Drug Development Compensation: $850kBarbara LindheimConsulting Vice President of Investor & Public Relations, Strategic Communications More Insider Trading Tools from MarketBeat Related Companies STRO Insider Trading EPIX Insider Trading PYXS Insider Trading ADAP Insider Trading IGMS Insider Trading TNYA Insider Trading IMMX Insider Trading ELUT Insider Trading ANRO Insider Trading VTGN Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Summer Stocks With Insider Buying and Analyst Support3 Tightly-Held Growth Stocks Set Up for Short SqueezesTankers, Takedowns & Air Taxis: Insiders Are Buying These 3 Names3 Tech Stocks Insiders Are Buying: Speculative Plays for JuneDividend Investors Looking for an Edge? 3 Stocks Insiders Bought This page (NASDAQ:CMMB) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemomab Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chemomab Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CMMB Stock Free CMMB Stock Alerts